News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

STRIDE regimen benefit in unresectable HCC consistent across baseline liver function
11 Sep 2022
byRoshini Claire Anthony
The overall survival (OS) benefit observed with the STRIDE regimen compared with sorafenib in patients with unresectable hepatocellular carcinoma (HCC) is consistent regardless of baseline liver function, according to exploratory analysis of data from the phase III HIMALAYA trial presented at ESMO GI 2022.
11 Sep 2022







